Radiance Biopharma Inc. bought its way into the ROR1 antibody-drug conjugate (ADC) space through a potential $1 billion-plus licensing deal, including a $15 million up-front payment, with CSPC ...

Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing ...

Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, ...

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...

The study showed that medicine used to help asthma patients for more than 20 years could lessen or prevent acute allergic ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...